Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Research Open Access Shelley D. Dougan, Nan Okun, Kara Bellai-Dussault, Lynn Meng, Heather E. Howley, Tianhua Huang, Jessica Reszel, Andrea Lanes, Mark C. Walker and Christine M. Armour CMAJ August 03, 2021 193 (30) E1156-E1163; DOI: https://doi.org/10.1503/cmaj.202456 Abstract BACKGROUND: The emergence of cell-free fetal DNA (cfDNA) testing technology has disrupted the landscape of prenatal screening for trisomies 21 (T21) and 18 (T18).
Letters Ann Kinga Malinowski, John Snelgrove and Nan Okun CMAJ June 08, 2020 192 (23) E634; DOI: https://doi.org/10.1503/cmaj.75807 We agree with Cheng and colleagues regarding the need to generate robust evidence through randomized trials.1 However, we note that inclusion of pregnant individuals is conspicuously absent from this call to action. Of investigations related to coronavirus disease 2019 (COVID-19) registered on clinicaltrials.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.